Abstract
Overview
Introduction
With growing competition, Pharma companies are under increased pressure to
deliver additional value for key stakeholders through their portfolios.
Companies with comprehensive portfolios offering more to physicians, patients,
payers and pharmacists will have the competitive edge.
Scope
- An overview of the current trends in pharmaceutical portfolio management
- Analysis of the ways in which pharmaceutical companies can develop their
portfolios to add value to key stakeholders
- Case study analysis of recent portfolio challenging scenarios and what
strategies were, or could be employed, in such situations
Highlights
Achieving a balanced portfolio in terms of new product development, lifecycle
management and business development and licensing is key to reducing risk and
growing franchise sales. With patent expiry of key blockbuster drugs
approaching lifecycle management is very popular but over reliance on this
approach can damage long-term prospects
Niche and specialty therapies are gaining ground over primary care portfolios,
but growing competition and a tougher pricing and reimbursement environment do
not make this an easy direction to follow
Payers have greater power than ever, and are increasingly influencing
physicians' treatment choices. Therefore, pricing and reimbursement analysis
needs to be incorporated into portfolio revision process as early as possible
in drug development.
Reasons to Purchase
- Understand the key issues in the pharmaceutical marketplace that are
putting a strain on drug portfolios
- Understand the recent trends in portfolio development strategies and learn
from best practice
- Gain an insight into how pharmaceutical companies are responding to
situations that are challenging their marketed and R&D portfolios
View Cart
